Compare BridgeBio Pharma Inc (BBIO) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Snap On Incorporated — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Snap On Incorporated trades at $412.41 (market cap $21.27B). The key difference: Snap On Incorporated is the larger of the two by market cap, and Snap On Incorporated pays a 2.37% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SNA | |
|---|---|---|
Market Cap | $16.61B | $21.27B |
Sector | Health | Technology |
52-Week High | $90.17 | $419.31 |
52-Week Low | $47.29 | $321.38 |
Enterprise Value | $18.16B | $20.90B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Snap-on Incorporated (SNA) trades at $416.35, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong support near $413. The company reported Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% driven by tools and diagnostics. Recent acquisitions like Diesel Laptops for $100 million expand its heavy-duty diagnostics reach, while solid cash flow and a 19.6% net income margin underscore operational strength.
SNA offers a compelling investment case with robust profitability, strategic growth initiatives, and a consensus price target of $455.33 implying 9.4% upside. Risks include integration costs from acquisitions, premium valuation multiples, and potential macroeconomic pressures on automotive demand. Analyst sentiment is positive with 65% buy ratings, but execution on growth initiatives remains key to justifying current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
